Advance Nanotech Expands Leadership Team; Nanotechnology Leader Appoints Dr. Michael N. Helmus To Head BioPharma Group
"Dr. Helmus possesses three decades of experience in medical device research and business development. His expertise in assessing the cost-effectiveness of next generation implants, devices and tissue engineered constructs will help guide Advance Nanotech's BioPharma Group," said Gittins. "We look forward to working with Dr. Helmus as we expand and grow the Advance Nanotech portfolio."
“Dr. Helmus possesses three decades of experience in medical device research and business development. His expertise in assessing the cost-effectiveness of next generation implants, devices and tissue engineered constructs will help guide Advance Nanotech's BioPharma Group”
Before joining Advance Nanotech Dr. Helmus served as the Vice President, Advanced Biomaterials at Boston Scientific. Prior to that Dr. Helmus held research and development positions with organizations including Edwards Lifesciences, Baxter CVS, Pfizer, and Arthur D. Little. Dr. Helmus holds a PhD and an MS in Biomedical Engineering from Case Western Reserve University and a BS in Metallurgy and Materials Science from Lehigh University. Dr. Helmus' expertise includes the identification and acquisition of new technologies, implementation and management of research and development programs, and intellectual property development and management. In the course of his career Dr. Helmus has been issued 26 U.S. patents, authored 47 technical publications and written 29 technology and market assessments.
Advance Nanotech is currently funding 18 portfolio companies in the electronics, biopharma, and materials industries. The firm provides services ranging from funding, to human capital and research equipment essential to ensuring that the most promising companies can accelerate the path to rapid commercialization. In this way, investor exposure to any particular technology is mitigated with Advance Nanotech retaining the option to increase investment in those technologies that successfully mature. Dr. Helmus will be responsible for overseeing the firm's biopharma-related investments.
About Advance Nanotech, Inc.
Advance Nanotech Inc. is dedicated to ensuring nanotechnology discoveries reach maximum market potential through successful commercialization. Advance is the trusted guide to commercial success for nanotech entrepreneurs spanning the globe, partnering with leading universities to provide scientists and researchers with mission critical infrastructure support to transform their discoveries to marketable solutions. The organization provides a range of services and support including financing, leadership assets and counsel on intellectual property, licensing and regulatory issues. With a portfolio of nearly 20 companies developing technologies which offer potentially breakthrough nanotechnology discoveries in the electronics, biopharma and materials sectors, Advance's goal is to transform the potential for nanotechnology discoveries into innovative products that further evolve existing industries and enable new markets.
This document contains forward-looking statements by Advance Nanotech regarding its expectations as to its business, and involves risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those addressed in the forward-looking statements.
Factors that may cause such a difference include, but are not limited to, problems and risks associated with developments in the nanotechnology industry in general and in Advance Nanotech's products under development in particular; the potential failure of Advance Nanotech's products under development to prove safe and effective in application; uncertainties inherent in the early stage of Advance Nanotech's products under development; failure to successfully implement or complete research programmes; failure to receive marketing clearance from regulatory agencies for our products under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Advance Nanotech's business, structure or projections; the development of competing products; uncertainties related to Advance Nanotech 's dependence on third parties and partners; and those risks described Advance Nanotech 's filings with the SEC. Advance Nanotech disclaims any obligation to update these forward-looking statements.
Further information about these and other relevant risks and uncertainties may be found in the Advance Nanotech's findings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.